Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.44 |
| ▸ | DRD2 | P14416 | 6/20 | 0.38 |
| ▸ | PRCP | P42785 | 4/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20883770 | 0.84 | ALDH1A1 (0.46) | TLR9TLR8TLR7DRD2PRCP | |
| SCHEMBL22542112 | 0.84 | DRD2 (0.43) | TLR9TLR8TLR7DRD2HTR2A | |
| SCHEMBL24478677 | 0.81 | DRD2 (0.41) | TLR9TLR8TLR7DRD2HTR2A | |
| SCHEMBL14924095 | 0.80 | HTR2A (0.43) | DRD2HTR2ASLC6A4 | |
| SCHEMBL24451719 | 0.79 | SIGMAR1 (0.42) | DRD2PRCPHTR2ASLC6A4 | |
| SCHEMBL20883742 | 0.79 | SLC6A2 (0.46) | DRD2DRD3SLC6A4 | |
| SCHEMBL20883769 | 0.77 | TACR2 (0.43) | DRD2PRCPHTR2ADRD3 | |
| SCHEMBL20668683 | 0.77 | SLC6A2 (0.40) | SLC6A4 | |
| SCHEMBL20884922 | 0.76 | MCOLN3 (0.39) | DRD2HTR2A | |
| SCHEMBL20883542 | 0.75 | KDM2B (0.40) | SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162229-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-05-26 | — | — | US | disclosed |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | TLR9 4530/4885TLR8 3748/4885TLR7 4610/4885 |
| US-20220162229-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | TLR9 4530/4885TLR8 3748/4885TLR7 4610/4885 |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | WEE1, WEE2, CCNE1 | TLR9 4760/4885TLR8 4360/4885TLR7 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.